pancreatic beta News
-
NIH/NIDDK Phase I SBIR Awarded Sept 2016
Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell ...
-
Peptides for Diabetes Research—a Special Offer of BOC Sciences
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
By BOC Sciences
-
New AMPK Pathways Offered to Support Metabolism Research
CD BioSciences, a US-based life science research product supplier and CRO, proudly offers AMPK Pathway to the life science community for researchers focusing on diabetes and metabolism study. These new signaling pathways and previously launched metabolic signaling pathways, such as insulin signaling pathway and mTOR pathway, will help support scientists in all aspects of cell death study. 5' ...
-
CD BioSciences Releases Insulin Signaling Pathway for Researchers
CD BioSciences, a US-based life science research product supplier and CRO, recently introduces new insulin signaling pathways to the life science community for research uses. These new signaling pathways in combination with other metabolic signaling pathways, such as TOR pathway, and AMPK pathway can cover all aspects of cell death study for researchers. Metabolism describes the life-sustaining ...
-
NIH/NIDDK Phase I SBIR Awarded Sept 2016
Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening ...
-
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you